Glioblastoma recurrence correlates with NLGN3 levels

Area of Science:

• Neuroscience
• Oncology
• Molecular Biology

Background:

• Glioblastoma (GBM) is a highly aggressive brain cancer with frequent recurrence.
• GBM recurrence typically occurs in deep brain structures like the basal ganglia, thalamus, and corpus callosum.
• The underlying mechanisms driving GBM recurrence in these specific regions remain unclear.

Purpose of the Study:

• To investigate the role of neuroligin-3 (NLGN3) in GBM recurrence in deep brain regions.
• To determine if NLGN3 levels correlate with GBM growth in specific brain areas.
• To elucidate the potential contribution of NLGN3 to GBM recurrence.

Main Methods:

• Retrospective analysis of 386 GBM cases (2013-2016).
• Comparative analysis of NLGN3 levels in normal human and mouse brains versus GBM patient brains.
• In vitro cell culture experiments using U251, U87-MG, and patient-derived GBM cells with cortex and basal ganglia neuron culture media.
• Assessment of cell growth and inhibition of NLGN3 release using ADAM10 inhibitor (ADAM10i).

Main Results:

• GBM recurrence predominantly observed in deep brain regions (basal ganglia, thalamus, corpus callosum).
• NLGN3 levels are higher in deep brain regions of GBM patients compared to normal brains.
• Increased NLGN3 concentration significantly promotes the growth of GBM cell lines and patient-derived cells.
• Inhibition of NLGN3 release by ADAM10i effectively prevents NLGN3-induced cell proliferation.

Conclusions:

• Elevated NLGN3 levels in deep brain regions under GBM pathological conditions may drive tumor recurrence.
• NLGN3 plays a crucial role in promoting GBM cell growth, particularly in the context of deep brain environments.
• Targeting NLGN3 release presents a potential therapeutic strategy to prevent GBM recurrence in susceptible brain regions.